8-K filed May 6, 2026, 7:59 PM ET ticker LXRX CIK 0001062822

debt confidence high sentiment neutral materiality 0.70

Lexicon secures $100M loan facility from Hercules Capital; $55M funded at closing

LEXICON PHARMACEUTICALS, INC.

Initial $55M tranche drawn at closing to repay existing Oxford Finance loan; second $20M and third $25M tranches available subject to milestones.
Interest rate = prime + 3.10% with 9.85% floor; initial 18-month interest-only period extendable to 30 months upon achieving clinical/regulatory milestones.
Loan matures May 4, 2030; secured by first lien on all assets; minimum cash covenant starts June 1, 2027.
Hercules received warrants to buy 691,823 shares at $1.59 per share; additional warrants up to 566,037 shares upon future tranche draws.
Funds support Lexicon's late-stage cardiometabolic pipeline including sotagliflozin HCM trial and potential regulatory filings.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001062822-26-000094
form_type: 8-K
ticker: LXRX
cik: 0001062822
company_name: LEXICON PHARMACEUTICALS, INC.
filed_at: 2026-05-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:31.894364+00:00
generated_at: 2026-05-14T22:27:19.400107+00:00
sec_items: ["1.01", "2.03", "3.02", "7.01", "9.01"]
event_type: debt
sentiment: neutral
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001062822-26-000094
json_url: https://secwatch.observer/filing/0001062822-26-000094.json
markdown_url: https://secwatch.observer/filing/0001062822-26-000094.md
text_url: https://secwatch.observer/filing/0001062822-26-000094.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/lxrx-20260504.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

149edfb578accf5e88e4c346b388bca003e13f0c

LEXICON PHARMACEUTICALS, INC. incurred credit facility of up to $100 million in borrowing capacity with Hercules Capital, Inc. and certain of its affiliates at prime rate plus 3.10%, but not less than 9.85% maturing May 2030.

On May 4, 2026, Lexicon Pharmaceuticals, Inc. (" Lexicon ") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (" Hercules ") that provides up to $100 million in borrowing capacity (the " Hercules Term Loans ") available in three tranches, each maturing in May 2030.

SEC 8-K Item 2.03/2.04 confidence 1.0 SEC evidence

43742554bb6608ff63d5b937339afda5ec688408

LEXICON PHARMACEUTICALS, INC. entered into Loan and Security Agreement with Hercules Capital, Inc. and certain of its affiliates valued at up to $100 million (effective 2026-05-04).

On May 4, 2026, Lexicon Pharmaceuticals, Inc. (“ Lexicon ”) and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (“ Hercules ”) that provides up to $100 million in borrowing capacity

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

EMAT

EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued

Evolution Metals & Technologies Corp. May 11, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 7.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 7.01, 9.01 same event type: debt similar materiality

This filing

On May 4, 2026, Lexicon Pharmaceuticals, Inc. (" Lexicon ") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (" Hercules ") that provides up to $100 million in borrowing capacity (the " Hercules Term Loans ") available in three tranches, each maturing in May 2030.

Comparable filing

The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.

Filing page SEC filing

TBH

Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger

Brag House Holdings, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On May 4, 2026, Lexicon Pharmaceuticals, Inc. (" Lexicon ") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (" Hercules ") that provides up to $100 million in borrowing capacity (the " Hercules Term Loans ") available in three tranches, each maturing in May 2030.

Comparable filing

The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027

Filing page SEC filing

KNX

Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver

Knight-Swift Transportation Holdings Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 8.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On May 4, 2026, Lexicon Pharmaceuticals, Inc. (" Lexicon ") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (" Hercules ") that provides up to $100 million in borrowing capacity (the " Hercules Term Loans ") available in three tranches, each maturing in May 2030.

Comparable filing

On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the "Company") completed its previously announced private offering (the "Offering") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031

Filing page SEC filing

PUMP

ProPetro issues $690M zero-coupon convertible notes due 2031, expands credit facility

ProPetro Holding Corp. May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 8.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On May 4, 2026, Lexicon Pharmaceuticals, Inc. (" Lexicon ") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (" Hercules ") that provides up to $100 million in borrowing capacity (the " Hercules Term Loans ") available in three tranches, each maturing in May 2030.

Comparable filing

On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031

Filing page SEC filing

OCGN

Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan

Ocugen, Inc. May 7, 2026, 7:59 PM ET debt Items 1.01, 1.02, 2.02, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On May 4, 2026, Lexicon Pharmaceuticals, Inc. (" Lexicon ") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (" Hercules ") that provides up to $100 million in borrowing capacity (the " Hercules Term Loans ") available in three tranches, each maturing in May 2030.

Comparable filing

On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”).

Filing page SEC filing

RNST

Renasant prices $300M 6.25% sub notes due 2036, net $295.7M, may redeem $40M 5.50% notes

RENASANT CORP May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 7.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 7.01, 9.01 same event type: debt similar materiality

This filing

On May 4, 2026, Lexicon Pharmaceuticals, Inc. (" Lexicon ") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (" Hercules ") that provides up to $100 million in borrowing capacity (the " Hercules Term Loans ") available in three tranches, each maturing in May 2030.

Comparable filing

for the issuance and sale of $300 million aggregate principal amount of its 6.25% Fixed-to-Floating Rate Subordinated Notes due 2036

Filing page SEC filing

HR subsidiary issues $700M 3.00% exchangeable senior notes due 2032

Healthcare Realty Trust Inc May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On May 4, 2026, Lexicon Pharmaceuticals, Inc. (" Lexicon ") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (" Hercules ") that provides up to $100 million in borrowing capacity (the " Hercules Term Loans ") available in three tranches, each maturing in May 2030.

Comparable filing

issued $700,000,000 aggregate principal amount of its 3.00% Exchangeable Senior Notes due 2032

Filing page SEC filing

VVX

V2X refinances $868.5M term loans with new tranche maturing 2030; SOFR+2% margin

V2X, Inc. June 1, 2026, 4:10 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On May 4, 2026, Lexicon Pharmaceuticals, Inc. (" Lexicon ") and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (" Hercules ") that provides up to $100 million in borrowing capacity (the " Hercules Term Loans ") available in three tranches, each maturing in May 2030.

Comparable filing

The Amendment provides for, among other things, a new tranche of term loans under the Credit Agreement in an aggregate original principal amount of $868,522,978.38 (the “New Term Loans”), which New Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), as further set forth in the Amendment. The New Term Loans mature on December 6, 2030.

Filing page SEC filing

Source: SEC EDGAR

accession 0001062822-26-000094

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.